Loading
A phase 2 trial of Samarium-153 lexidronam in Prostate cancer, run by Radiation Therapy Oncology Group, completed.
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer is a phase 2 interventional study registered as NCT00551525 by Radiation Therapy Oncology Group, with 67 participants recorded, started 2008-04 and reaching its primary completion in 2014-07. Interventions recorded: Radiotherapy, Samarium 153. Conditions recorded: Prostate Cancer.
Linked to the drug Samarium-153 lexidronam because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
67 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2017-07-25), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Proportion of Patients With PSA Response (pt) Within 12 Weeks of Samarium 153 Administrationprimary | Radiotherapy + Samarium 153 | 52 | 7% | - | - | link |
Shares Samarium-153 lexidronam, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Samarium-153 lexidronam and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares NRG Oncology, Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.